ADR Biomedical Holdings (TSE:3750) NonCurrent Deferred Liabilities: 円0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
31 GF Score
Price 円778.00
GF Value 円39.95
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings NonCurrent Deferred Liabilities?

ADR Biomedical Holdings TSE:3750 -2.75% 31 NonCurrent Deferred Liabilities is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 31/100 and a GF Value™ of 円39.95 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

ADR Biomedical Holdings's non-current deferred liabilities for the quarter that ended in Mar. 2026 was 円0.00 Mil.

ADR Biomedical Holdings NonCurrent Deferred Liabilities Related Terms

ADR Biomedical Holdings NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings NonCurrent Deferred Liabilities Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ADR Biomedical Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:3750
31GF Score
ADR Biomedical Holdings Inc TSE:3750
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of 円0.00 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a NonCurrent Deferred Liabilities of 円0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' NonCurrent Deferred Liabilities too high?
ADR Biomedical Holdings' current NonCurrent Deferred Liabilities is 円0.00 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' NonCurrent Deferred Liabilities compare to VRTX and REGN?
ADR Biomedical Holdings' NonCurrent Deferred Liabilities of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current NonCurrent Deferred Liabilities is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.95, compared to a current price of 円778.00 — trading 1847.4% above its estimated fair value. The current NonCurrent Deferred Liabilities is 円0.00 Mil. ADR Biomedical Holdings' overall GF Score™ is 31/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current NonCurrent Deferred Liabilities is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円778.00 is trading 1847.4% above its estimated GF Value™ of 円39.95. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • NonCurrent Deferred Liabilities: 円0.00 Mil
  • GF Value™: 円39.95 vs. price of 円778.00 (1847.4% above fair value)
  • GF Score™: 31/100 with 9 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
31GF Score

Get the complete analysis for TSE:3750

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円778.00
Price
円39.95
GF Value